Resting Energy Expenditure in Pediatric Patients With Inflammatory Bowel Disease (REE-MICI)
Observational · No treatment assigned · 1 site · Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: Crohn Disease Colitis, Colitis, Ulcerative and Inflammatory Bowel Diseases. This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 6 to 17
- Any sex
Some of the main requirements, copied from the record:
- Pediatric patients aged 6 to 17 years
- New diagnosis of inflammatory bowel disease, including Crohn disease or ulcerative colitis, according to ECCO/ESPGHAN criteria
- Written informed consent signed by parents or legal guardians
There are also 3 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 50 participants are expected to take part.
- Start date: 2025-05-01.
- Main results expected around 2027-03 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Italy.
Main thing being measured
- Resting Energy Expenditure measured by indirect calorimetry (Baseline, 2 months, and 9 months after diagnosis)
In the researchers’ words
This multicenter prospective observational non-pharmacological study aims to evaluate resting energy expenditure (REE) in pediatric patients affected by inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. REE will be measured using indirect calorimetry and estimated using predictive equations.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | Crohn Disease Colitis; Colitis, Ulcerative; Inflammatory Bowel Diseases |
| Lead sponsor | Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria |
| Enrollment | 50 (estimated) |
| Start date | 2025-05-01 |
| Primary completion (est.) | 2027-03 |
| First posted | 2026-06-26 |
| Last updated | 2026-06-26 |
| Official title | Measurement of Basal Metabolism in Patients With Crohn's Disease and Ulcerative Colitis and Correlation With Disease Activity. |
| ClinicalTrials.gov ID | NCT07670975 |
Interventions
- Indirect Calorimetry (Diagnostic Test)
Resting energy expenditure (REE) assessment performed using indirect calorimetry in pediatric patients with inflammatory bowel disease during routine clinical follow-up. Measurements are obtained under resting conditions after fasting and are used to evaluate energy metabolism and its relationship with disease activity and treatments.
Full eligibility criteria (from the record)
Inclusion Criteria: * Pediatric patients aged 6 to 17 years * New diagnosis of inflammatory bowel disease, including Crohn disease or ulcerative colitis, according to ECCO/ESPGHAN criteria * Written informed consent signed by parents or legal guardians Exclusion Criteria: * Intestinal surgery within 6 weeks before the first evaluation * Parenteral or enteral nutrition within 6 weeks before the first evaluation * Eating disorders or other chronic diseases associated with possible malabsorption
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Pediatric Unit | Alessandria, Piedmont | Italy | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.